PRRT2 and cancer: Dysregulated PKC activity is implicated in cancer progression (Isakov, 2018; Cooke et al., 2017), cardiac disease (Singh et al., 2017), diabetes (Rask-Madsen and King, 2005), and neurodegenerative disorders (Lordén and Newton, 2021).